These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. de Lastours V; Ferrari Rafael De Silva E; Daudon M; Porcher R; Loze B; Sauvageon H; Molina JM J Antimicrob Chemother; 2013 Aug; 68(8):1850-6. PubMed ID: 23599359 [TBL] [Abstract][Full Text] [Related]
6. Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir. Viglietti D; Verine J; De Castro N; Scemla A; Daudon M; Glotz D; Pillebout E Antivir Ther; 2011; 16(1):119-21. PubMed ID: 21311116 [TBL] [Abstract][Full Text] [Related]
7. Urolithiasis associated with atazanavir may mask a metabolic 'channelling' bias. Guaraldi G; Dolci G; Bellasi A J Antimicrob Chemother; 2014 Jan; 69(1):284-5. PubMed ID: 23934771 [No Abstract] [Full Text] [Related]
8. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E; Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947 [TBL] [Abstract][Full Text] [Related]
9. Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study. Lafaurie M; De Sousa B; Ponscarme D; Lapidus N; Daudon M; Weiss L; Rioux C; Fourn E; Katlama C; Molina JM PLoS One; 2014; 9(11):e112836. PubMed ID: 25409506 [TBL] [Abstract][Full Text] [Related]
10. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112 [TBL] [Abstract][Full Text] [Related]
15. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542 [TBL] [Abstract][Full Text] [Related]
16. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia. Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961 [TBL] [Abstract][Full Text] [Related]
18. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D; Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869 [TBL] [Abstract][Full Text] [Related]
19. Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult. Jacques AC; Giguère P; Zhang G; Touchie C; la Porte CJ Ann Pharmacother; 2010 Jan; 44(1):202-6. PubMed ID: 19955297 [TBL] [Abstract][Full Text] [Related]